DNA Q3 2025 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39M-56.4% YoY

Gross Profit

$26M67.0% margin

Operating Income

-$90M-231.8% margin

Net Income

-$81M-207.9% margin

EPS (Diluted)

$-1.45

QoQ Revenue Growth

-21.7%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$629M

Stockholders' Equity

$560M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$89M	-56.4%
Gross Profit	$26M	$79M	-67.1%
Operating Income	-$90M	-$55M	-63.1%
Net Income	-$81M	-$56M	-43.2%